Dinaciclib

Manufactured by Axon Medchem

Sourced in Netherlands

Dinaciclib is a small molecule inhibitor that targets cyclin-dependent kinases (CDKs). It is a potent and selective inhibitor of CDK1, CDK2, CDK5, and CDK9. Dinaciclib is used as a research tool in the study of cell cycle regulation and as a potential therapeutic agent for various types of cancer.

Automatically generated - may contain errors

Lab products found in correlation

Apotox glo triplex assay, by Promega (1 mentions) Rna imax reagent, by Merck Group (1 mentions) Celltiter glo luminescent cell viability assay, by Promega (1 mentions) Ldc000067, by Selleck Chemicals (1 mentions) At7519, by Selleck Chemicals (1 mentions) Incucyte caspase 3 7 green reagent for apoptosis, by Sartorius (1 mentions) Ro 3306, by Selleck Chemicals (1 mentions) Palbociclib, by Selleck Chemicals (1 mentions) Xav 939, by MedChemExpress (1 mentions) Temozolomide, by Merck Group (1 mentions) Olaparib, by Merck Group (1 mentions) Dinaciclib, by Merck Group (1 mentions) Olaparib, by Axon Medchem (1 mentions) Talazoparib, by Axon Medchem (1 mentions)

3 protocols using dinaciclib

High-throughput Assays for Cell Viability and Death

Check if the same lab product or an alternative is used in the 5 most similar protocols

OSMI-2 and OSMI-4 were synthesized in-house (10 (link)). AT7519, LDC000067, Palbociclib, RO3306 and
PHA848125 were purchased from Selleckchem. Staurosporine was purchased from
Abcam. Dinaciclib was from Axon Medchem. NVP2 and SB1317 were obtained from
MedChem Express. ATP levels in cells were assessed using the
CellTiter-Glo® Luminescent Cell Viability Assay (Promega). Colony-forming
assays were performed using the CytoSelect 384-well Cell Transformation Assay
(BioCat) according to manufacturer’s instructions. Growth rate and cell
death activation were evaluated using the Incucyte instrument according to
manufacturer’s instructions. For detection of cell death activation, we
used IncuCyte® Caspase-3/7 Green Reagent for Apoptosis (Essen
Biosciences). Cell death activation for Fig.
2E and Suppl. Fig.
3 were performed using the ApoTox-Glo™ Triplex Assay (Promega)
according to the manufacturer’s instructions (the signal from caspase
activity was normalized to signal from viable cells). Cycloheximide (CHX) was
used as a positive control to induce cell death0. Knockdown experiments were
performed using RNAiMax reagent (Sigma). OGT targeting siRNAs were from
ThermoFisher Scientific: siOGT_1 s16094 and siOGT_2 s16095 and CDK9 targeting
siRNA was from Qiagen (SI00024423).

Itkonen H.M., Poulose N., Steele R.E., Martin S.E., Levine Z.G., Duveau D.Y., Carelli R., Singh R., Urbanucci A., Loda M., Thomas C.J., Mills I.G, & Walker S. (2020). Inhibition of O-GlcNAc transferase renders prostate cancer cells dependent on CDK9. Molecular cancer research : MCR, 18(10), 1512-1521.

+ Open protocol

+ Expand

Dose-Titration Experiments with Small-Molecule Inhibitors

Check if the same lab product or an alternative is used in the 5 most similar protocols

Drugs were purchased for commercial sources or synthesized in house, as follow. Dinaciclib: Axon Medchem. SNS-032: Bio Vision. MGH-CP1: Enamine. MYF-01-37, VT-103, VT-107, K-975, XAV939: MedChem Express. Mivebresib (ABBV-075): Selleck. JQ1: Tocris. XAV939: XcessBio. MSC-4106, VT02956, LATSi (NCGC00886782): in-house. 10 mM stock solutions in DMSO were used as the starting point for all the dose-titration experiments.

Evsen L., Morris P.J., Thomas C.J, & Ceribelli M. (2023). Comparative Assessment and High-Throughput Drug-Combination Profiling of TEAD-Palmitoylation Inhibitors in Hippo Pathway Deficient Mesothelioma. Pharmaceuticals, 16(12), 1635.

+ Open protocol

+ Expand

Combinatorial Therapy Strategies in Cancer

Check if the same lab product or an alternative is used in the 5 most similar protocols

Different co-treatments or pre-treatment strategies were followed for each combined therapy. For liposomal doxorubicin and olaparib treatment, the cells were pre-treated for 6 h with 100 nM Dox-NP (Avanti^®, Alabaster, AL, USA), followed by treatment for 60 h with 1 μM olaparib. For temozolomide (TMZ) (Sigma Aldrich, Taufkirchen, Germany) and olaparib co-treatment, the cells were pre-treated for 48 h with 50 μM temozolomide before co-treatment with 1 μM olaparib for 24 h. Single treatments with [¹²⁵I]-PARPi-01 (~1 MBq/10⁶ cells), olaparib (1 μM), dinaciclib (5 μM; Sigma), and talazoparib (10 nM; Axon Medchem, Groningen, Netherlands.) were done for 72 h, dinaciclib (5 μM), and 1 μM olaparib co-treatment was done for 72 h. For Dox-NP and [¹²⁵I]-PARPi-01 combination, the cells were pre-treated with 100 nM Dox-NP 6 h prior to incubation with [¹²⁵I]-PARPi-01 (~1MBq/10⁶ cells) for 72 h. Untreated cells were incubated in growth medium supplemented with DMSO (≤0.2%) for 72 h.

Sankaranarayanan R.A., Peil J., Vogg A.T., Bolm C., Terhorst S., Classen A., Bauwens M., Maurer J., Mottaghy F, & Morgenroth A. (2022). Auger Emitter Conjugated PARP Inhibitor for Therapy in Triple Negative Breast Cancers: A Comparative In-Vitro Study. Cancers, 14(1), 230.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!